<DOC>
	<DOCNO>NCT00787137</DOCNO>
	<brief_summary>The primary objective evaluate safety tolerability single intravenous dose PG102 patient psoriatic arthritis . The secondary objective evaluate PG102 move around body explore effect disease .</brief_summary>
	<brief_title>Single Dose PG102 Patients With Active Psoriatic Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Arthritis meet Classification Psoriatic Arthritis ( CASPAR ) criteria Plaque psoriasis least 6 month prior study enrollment Clinically significant psoriasis flare Unstable dos pain relief medication Treatment systemic corticosteroid prednisone ≤ 10 mg/day equivalent Treatment biologic therapy Treatment immunosuppressive agent disease modify antirheumatic drug ( DMARDs ) methotrexate Treatment lithium , antimalarial , chlorambucil , cyclophosphamide therapy psoriasis low potency topical corticosteroid intertriginous groin area , tar salicylate preparation scalp , emollients moisturisers Family history multiple thrombotic event personal history venous arterial thrombotic event Clinically significant result anticardiolipin , Activated protein C resistance test , Protein C , Free Protein S , Antithrombin III , Factor V Leiden , Prothrombin variant , Homocysteine , Lupus anticoagulant , Prothrombin time , Activated partial thromboplastin time , Fibrinogen , Thrombin time , Factors IX XI Currently smoke ≥ 10 cigarette per day equivalent Active tuberculosis infection Current previous malignancy Clinically significant abnormality physical examination , laboratory testing , vital sign 12lead electrocardiogram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>